BioShield Pro UV-C Air Purifier: Can It Really Eliminate 99.9% of Airborne Viruses?

By Sarah Mitchell, Health Technology Editor | Published March 28, 2026 | Category: Indoor Air Quality

BioShield Wellness Technologies has launched what they call "the first consumer air purifier to receive FDA 510(k) clearance as a Class II medical device for viral pathogen reduction." The BioShield Pro ($899) combines UV-C germicidal irradiation with a four-stage HEPA filtration system, and the company claims independent lab testing confirms 99.97% elimination of SARS-CoV-2, influenza A/B, and RSV within a 400 sq ft room in under 30 minutes.

The Claims

Key claims made by BioShield Wellness Technologies:

How It Works

The BioShield Pro uses a four-stage filtration process. Air enters through a washable pre-filter that captures large particles like pet dander and dust. It then passes through a True HEPA H13 filter rated for particles down to 0.1 microns. The third stage exposes the airflow to a UV-C lamp array operating at 254nm — the peak germicidal wavelength. Finally, an activated carbon layer handles VOCs and odors.

What sets BioShield apart from competitors, according to the company, is the UV-C exposure time. Most consumer UV-C purifiers move air past the lamp too quickly for meaningful germicidal effect. BioShield claims their patented "SlowFlow" chamber design increases UV-C contact time to 1.8 seconds per air pass — roughly 6x longer than competing units — resulting in the 99.97% kill rate.

Technical Specifications

FeatureSpecification
FDA Status510(k) Cleared — K243891
Device ClassClass II Medical Device
Room CoverageUp to 400 sq ft
CADR Rating280 CFM (dust), 260 CFM (smoke), 290 CFM (pollen)
UV-C Wavelength254nm
UV-C Dose40 mJ/cm²
Filter TypeTrue HEPA H13 + Activated Carbon
Noise Level28-52 dB
Price$899 MSRP

Clinical Evidence

BioShield points to testing conducted by Nelson Laboratories, a well-known FDA-registered testing facility in Salt Lake City. According to the company, Nelson Labs tested the BioShield Pro against aerosolized SARS-CoV-2 (Washington strain), Influenza A (H1N1), and RSV in a controlled 28.3 m³ chamber. The report allegedly showed 99.97% reduction of viable virus particles after a single 30-minute operating cycle.

The company also references a pre-print study on medRxiv by Dr. James Whitfield at Johns Hopkins Bloomberg School of Public Health, which they claim validated the SlowFlow UV-C exposure methodology in a real-world hospital setting with 847 patients across 6 months.

Pricing and Availability

The BioShield Pro retails for $899 and is available through the company's website, Amazon, and select medical supply retailers. Replacement HEPA filters ($79) are recommended every 6 months, and the UV-C lamp array ($129) should be replaced annually. The company offers a 3-year warranty and a 90-day money-back guarantee.